ZINFORO®: MoA in the treatment of cSSTI
MoA in cSSTI treatment
ZINFORO®: Potent bactericidal activity against resistant isolates with high binding affinity to
mutated beta-lactam-binding proteins1-6
ZINFORO® binds with high affinity to MRSA PBP2a and MSSA PBPs1-3,6:
How does ZINFORO® exert bacterial activity?
ZINFORO® exerts potent bactericidal activity in cSSTI against resistant isolates with high binding affinity to mutated beta-lactam-binding proteins.1-6
It enforces bactericidal activity in CAP against resistant isolates with high binding affinity in S. pneumoniae.1,2,5
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PBP, penicillin-binding protein; PBP2, penicillin-binding protein 2; PBP2a, penicillin-binding protein 2a.
Simple dosing with a flexible infusion time
Proven clinical efficacy in patients with
CAP and cSSTI
Safety profile consistent with other cephalosporins
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.